You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,694,100

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,694,100

Title:	Enzymatic wound debriding compositions with enhanced enzymatic activity
Abstract:	The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.
Inventor(s):	Shi; Lei (Mansfield, TX), Jovanovic; Aleksa (Fort Worth, TX), Aust; Duncan (Huntingdon Valley, PA)
Assignee:	Smith & Nephew, Inc. (Memphis, TN)
Application Number:	13/514,945
Patent Claims:	1. An anhydrous enzymatic wound debriding composition comprising: (a) a hydrophilic dispersed phase comprising PEG 400 and collagenase; and (b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase; wherein the amount of PEG 400 is 10-30% w/w of the composition, wherein the composition is anhydrous, and wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, and paraffin. 2. The anhydrous enzymatic wound debriding composition of claim 1, wherein the hydrophobic base is petrolatum. 3. The anhydrous enzymatic wound debriding composition of claim 1, wherein the amount of PEG 400 is 13-27% w/w of the composition. 4. The anhydrous enzymatic wound debriding composition of claim 3, wherein the amount of PEG 400 is 20% w/w of the composition. 5. An anhydrous enzymatic wound debriding composition comprising: (a) a hydrophilic dispersed phase comprising PEG 600 and collagenase; and (b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase; wherein the amount of PEG 600 is 20-40% w/w of the composition, wherein the composition is anhydrous, and wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, and paraffin. 6. The anhydrous enzymatic wound debriding composition of claim 5, wherein the hydrophobic base is petrolatum. 7. The anhydrous enzymatic wound debriding composition of claim 5, wherein the amount of PEG 600 is 23-37% w/w of the composition. 8. The anhydrous enzymatic wound debriding composition of claim 7, wherein the amount of PEG 600 is 30% w/w of the composition. 9. An anhydrous enzymatic wound debriding composition comprising: (a) a hydrophilic dispersed phase comprising Poloxamer 124 and collagenase; and (b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase; wherein the amount of Poloxamer 124 is 20-40% w/w of the composition, wherein the composition is anhydrous, and wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, and paraffin. 10. The anhydrous enzymatic wound debriding composition of claim 9, wherein the hydrophobic base is petrolatum. 11. The anhydrous enzymatic wound debriding composition of claim 9, wherein the amount of Poloxamer 124 is 23-37% w/w of the composition. 12. The anhydrous enzymatic wound debriding composition of claim 11, wherein the amount of Poloxamer 124 is 30% w/w of the composition. 13. The anhydrous enzymatic wound debriding composition of claim 1, wherein the composition is a liquid. 14. The anhydrous enzymatic wound debriding composition of claim 1, wherein the composition is a semi-solid. 15. The anhydrous enzymatic wound debriding composition of claim 1, wherein the composition is sterile. 16. The anhydrous enzymatic wound debriding composition of claim 5, wherein the composition is a liquid. 17. The anhydrous enzymatic wound debriding composition of claim 5, wherein the composition is a semi-solid. 18. The anhydrous enzymatic wound debriding composition of claim 5, wherein the composition is sterile. 19. The anhydrous enzymatic wound debriding composition of claim 9, wherein the composition is a liquid. 20. The anhydrous enzymatic wound debriding composition of claim 9, wherein the composition is a semi-solid. 21. The anhydrous enzymatic wound debriding composition of claim 9, wherein the composition is sterile.

Details for Patent 9,694,100

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.